co m m e nt a r y with the administration of active vitamin D metabolites. Reduced glomerular and tubulointerstitial alterations are accompanied by reduced proteinuria in experimental diabetic nephropathy and other experimental kidney disease. Reduced proteinuria with administration of active vitamin D was also confirmed in human subjects with chronic kidney disease. The reported increased susceptibility of the kidneys of VDR -/-mice to hyperglycemia might hold not only for diabetic nephropathy, but also for other chronic kidney diseases. These findings all suggest that vitamin D deficiency should be avoided in diabetic and nondiabetic chronic kidney disease. However, the effect of (low) doses of active vitamin D metabolites on development of diabetic nephropathy in patients with diabetes should be evaluated in prospective randomized clinical trials. 
with the administration of active vitamin D metabolites. Reduced glomerular and tubulointerstitial alterations are accompanied by reduced proteinuria in experimental diabetic nephropathy and other experimental kidney disease. Reduced proteinuria with administration of active vitamin D was also confirmed in human subjects with chronic kidney disease. The reported increased susceptibility of the kidneys of VDR -/-mice to hyperglycemia might hold not only for diabetic nephropathy, but also for other chronic kidney diseases. These findings all suggest that vitamin D deficiency should be avoided in diabetic and nondiabetic chronic kidney disease. However, the effect of (low) doses of active vitamin D metabolites on development of diabetic nephropathy in patients with diabetes should be evaluated in prospective randomized clinical trials. Chronic kidney disease is often characterized by a progressive loss of renal function, and the start of dialysis further decreases residual renal function (RRF). This is of particular concern because RRF and diuresis are known to be major determinants of patient survival and, at least in the case of peritoneal dialysis, technique survival. It is therefore not surprising that nephrologists are interested in evidence-based data concerning the best strategies for preserving renal function in patients on dialysis.
The results of observational studies have shown that high-flux biocompatible membranes not only reduce serum β 2 -microglobulin levels more efficiently than low-flux bioincompatible membranes but also lead to a lower incidence of dialysisrelated amyloidosis and improve lipid profiles, peripheral nerve conductivity, and the susceptibility to infection. 1 Even more important for the purposes of this Commentary is that the use of high-flux biocompatible membranes had been associated with a slower decrease in RRF in previously reported cohort studies. 2 Cohort studies may have the advantage of being more representative of all patients in real everyday clinical practice, but they are limited by the fact that controlling for confounding factors is restricted to what is already known and, although they can reveal associations, they can never prove causation. Furthermore, their positive findings are often contradicted by the surprising results of randomized controlled trials.
One clear example of this is the Hemodialysis (HEMO) Study, 3 which not only failed to confirm previous observational data indicating that more dialysis is better but, even more importantly, did not support the view that high-flux biocompatible dialysis is better than low-flux dialysis. However, the preliminary results of the Membrane Permeability Outcome study 4 presented at the European Renal Association-European Dialysis and Transplant Association Congress in Barcelona in June seem to challenge the HEMO findings.
As preservation of RRF is associated with improved patient survival, any approach that may accomplish it is welcome not only in the early stages of chronic kidney disease (in an attempt to prevent the need for dialysis), but also in patients with stage 5 chronic kidney disease who are already on dialysis.
co mmentar y
In order to assess the impact of the biocompatibility of hemodialysis membranes on RRF, one prospective study randomly allocated 20 normotensive patients with tubulointerstitial nephritis to treatment with biocompatible high-flux polysulfone or bioincompatible cellulose membranes for 12 months. 2 RRF decreased in both groups after the start of hemodialysis, but the decrease was faster in the patients treated with cellulose membranes. According to the authors, the pathophysiological mechanism underlying the more rapid decline of RRF in patients treated with cellulose membranes could not be explained by intradialytic hypotension but may be related to the nephrotoxic effects of inflammatory mediators due to membrane bioincompatibility. Unfortunately, the preliminary results of the Membrane Permeability Outcome study, 4 which enrolled more than 700 patients, do not confirm the positive results of this small trial.
As far as peritoneal dialysis is concerned, long-term changes in membrane structure (neoangiogenesis, advanced glycation end product formation, fibrosis, mesothelial denudation, and sub-mesothelial expansion) are responsible for functional alterations in peritoneal membranes, including increased small-solute transport and the loss of ultrafiltration capacity, and can progress to encapsulating peritoneal sclerosis, a rare but life-threatening complication of peritoneal dialysis.
The bioincompatibility of peritoneal dialysis fluids (PDFs) is their low pH, the presence of lactate as buffer, hyperosmolality, and the presence of glucose and glucose degradation products (GDPs), which means that the requirements for more biocompatible PDFs are a physiological pH, a more balanced buffer system, little or no glucose, and reduced GDP production.
Multicompartmental bag systems increase pH, minimize the generation of GDPs during PDF heat sterilization, and introduce bicarbonate as a buffer. Furthermore, multicompartmental solutions have proved to be superior to conventional PDFs during in vitro tests and in vivo trials using surrogate end points such as the dialysate concentration of cancer antigen 125 (CA125). These trials have shown increased CA125 concentrations in effluent fluid, and, although the clinical significance of CA125 is not entirely clear, it is likely that CA125 levels reflect mesothelial-cell mass; so increased levels may be an index of a more preserved peritoneal mesothelium. Furthermore, a decrease in intraperitoneal hyaluronan levels may reflect reduced irritation of the peritoneal membrane. Measuring the dialysate levels of other markers (procollagen I peptides, transforming growth factor-β, vascular endothelial growth factor, tumor necrosis factor-α, and so on) did not lead to unequivocal results. Thus it has been suggested that the use of biocompatible solutions is associated with a more preserved peritoneal membrane.
The use of more biocompatible dialysis solutions in clinical practice has been associated, in a retrospective study, with better survival, albeit without any association with peritoneal technique survival or the rate of peritonitis. 5 These results have been interpreted as being possibly due to the better preservation of RRF in the patients treated with more biocompatible solutions, 5 and this is supported by the findings of the EuroBalance Trial, 6 although this also has some methodological drawbacks.
We find it difficult to believe that using a more biocompatible peritoneal dialysis solution (or more biocompatible co m m e nt a r y membranes) for a relatively short period of time can independently affect the RRF of dialysis patients significantly, because of the many confounding variables involved, including the correct estimation of the patients' dry body weight, which, in our opinion, is probably the most important factor affecting the preservation of RRF and diuresis. In the Euro-Balance Trial, 6 hypervolemia may have contributed to preserving RRF in the patients randomized to the biocompatible solutions. Furthermore, it is necessary to consider the use of drugs, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, that may greatly affect RRF by improving or worsening renal function; in addition, it is always difficult to ensure the balanced distribution of these drugs among the patients randomized to different treatments in controlled trials, as well as the delicate question of patients' compliance with their prescription, which can be a major confounding factor. Other important factors possibly affecting RRF are infections (including peritonitis in peritoneal dialysis patients) and the potentially nephrotoxic antibiotics needed to treat them. Fan et al. 7 (this issue) now describe a well-planned prospective (albeit openlabel) study designed to analyze the potential benefit of neutral-pH, low-GDP 'biocompatible' peritoneal dialysis solutions in relation to RRF. The results strongly suggest that such solutions do not have any major advantage over standard solutions in patients on continuous ambulatory or automated peritoneal dialysis. The study also analyzed the effect of these solutions on membrane function and technique survival, once again finding no significant differences.
The authors themselves acknowledge that the study was underpowered to examine the impact on peritonitis and technique survival, 7 but, given the very few prospective randomized trials in this field (Table 1) , we find it interesting even with these limitations. The previously reported associations between improved survival and biocompatible solutions, suggesting that preserved RRF could be a possible explanation, were derived from retrospective analyses or small trials, rather than a randomized, adequately sized, controlled trial designed for this purpose.
In line with the well-known view of 'the earlier the prevention, the better, ' it has been clearly demonstrated that earlier interventions are much more successful in preserving renal function in patients with early-stage chronic kidney disease. The possible effect of more biocompatible peritoneal dialysis solutions on RRF should therefore be further tested in patients starting peritoneal dialysis programs with relatively well-preserved RRF. When RRF is already very poor, it is very difficult to believe that a more biocompatible peritoneal dialysis solution can preserve highly damaged and sclerotic kidneys, and we strongly believe that hemodynamic factors may be much more important, including correctly evaluating patient dry body weight, balancing the risk of overhydration with the risk of jeopardizing RRF, and avoiding potentially nephrotoxic drugs and carefully using those that are potentially nephroprotective.
However, we do agree that using a more biocompatible peritoneal dialysis solution may reduce the rate of infections (peritonitis) and thus reduce the risks associated with the potentially nephrotoxic antibiotics used to treat them, and we cannot rule out the possibility that this may help to preserve RRF.
